Targeting HER2 expression in cancer: New drugs and new indications

Semir Vranić1*, Semir Bešlija2, Zoran Gatalica3,4

ABSTRACT

Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown to strongly promote carcinogenesis, leading to the investigation of HER2-directed agents in cancers with HER2 genomic alterations. This has been best documented in the context of HER2 gene amplification in breast and gastric/gastroesophageal junction carcinomas for which several HER2-directed agents are available and have become a part of standard treatment regimens. Somatic HER2 gene mutations have been recently described at low frequency in a variety of human cancers and have emerged as a novel predictive biomarker for HER2-directed therapies. Preclinical data also indicate that activating HER2 mutations are potent oncogenic drivers in a manner that is analogous to HER2 amplification. HER2 mutations may clinically confer sensitivity to HER2-directed agents as recently shown in a phase II clinical trial with antibody-drug conjugate against HER2 trastuzumab deruxtecan in patients with non-squamous non-small cell lung carcinoma.

KEYWORDS: HER2; targeted therapy; mutations; amplification

The oncogenic potential and activation of human epidermal growth factor receptor 2 (HER2) has been well established in several human malignancies, most notably in breast and gastric/gastroesophageal junction (GEJ) carcinomas. The primary mechanism of the HER2 activation in these cancers is HER2 gene amplification that leads to the complete HER2 protein overexpression on the cellular membrane [1,2]. In recent years, other genomic alterations of HER2 have also been recognized leading to protein activation among which HER2 gene mutations represent the most important form [3]. HER2 mutations are usually of activating type and the majority of them are seen without concurrent HER2 gene amplification [3-5]. The highest prevalence (>10%) of HER2 mutations has been observed in prostate neuroendocrine carcinomas, metastatic cutaneous squamous cell carcinomas and urothelial bladder carcinoma. Additionally, HER2 mutations have also been reported in common cancers such as pulmonary, colorectal and breast cancers, indicating a potential for HER2-directed therapies in these cancers [4,6-12]. HER2 mutations are enriched in certain specific histological subtypes, for instance in invasive lobular carcinoma of the breast (5-18%) [13-15] and in ~2-3% of pulmonary adenocarcinomas [16-21]. Recently, HER2 mutations were reported to occur more frequently in microsatellite stable (MSS) colorectal carcinomas than in microsatellite stable (MSI-H) colorectal carcinomas [22]. Studies in non-small cell lung carcinomas (NSCLC) revealed mutations affecting predominantly exon 20 and were seen without amplification of HER2 gene. In addition, HER2 mutations were mutually exclusive with other common oncogenic drivers in NSCLC. In contrast to epidermal growth factor receptor (EGFR) mutations, the frequency of HER2 mutations appear to be similar between Asian and Caucasian populations [16].

The anti-HER2 antibody trastuzumab has been a cornerstone of effective therapy in treatment of HER2-positive breast and gastric cancers. However, the number of approved anti-HER2 therapeutic agents has been markedly expanded in recent years, with the addition of tyrosine kinase inhibitors (lapatinib, neratinib, tucatinib), antibodies (pertuzumab), and antibody-drug conjugates [ado-trastuzumab emtansine (T-DM1)] and trastuzumab deruxtecan (DS-8201) [summarized in Table 1] [3]. Used alone or in combination with other targeting agents or conventional chemotherapeutics, these anti-HER2 agents have remarkably improved the outcome of patients with HER2-positive breast cancer [23, 24].

One of the most recent antibody-drug conjugates (ADC) against HER2 is trastuzumab deruxtecan (Enhertu; DS-8201; AstraZeneca and Daiichi Sankyo Company, Limited

---

1College of Medicine, QU Health, Qatar University, Doha, Qatar
2Department of Oncology, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina
3Creighton University School of Medicine, Phoenix, Arizona, United States
4Oklahoma University College of Medicine, Oklahoma City, Oklahoma, United States

*Corresponding author: Semir Vranić, College of Medicine, QU Health, Qatar University, PO Box 2713 Doha, Qatar. E-mail: semir.vranic@gmail.com or svranic@qu.edu.qa
ORCID: http://orcid.org/0000-0001-9743-7265
DOI: https://dx.doi.org/10.17305/bjbms.2020.4908
Submitted: May 30, 2020/Accepted: June 7, 2020
Conflict of interest statement: The authors declare no conflict of interests
Funding: None.

©The Author(s) (2021). This work is licensed under a Creative Commons Attribution 4.0 International License


www.bjbms.org
Semir Vranić, et al.: New HER2 treatments

(Daiichi Sankyo). It is composed of an anti-HER2 antibody (trastuzumab), a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I (TOP1) inhibitor ("payload") (Table 1). Previously, it was published that TOP1 was overexpressed in 63% of all invasive breast carcinomas [25]. Enhertu appears to exhibit a higher drug-to-antibody ratio than another anti-HER2 ADC trastuzumab emtansine (Kadsyla) (approximately 8 vs. 3-4) while retaining a favorable pharmacokinetic characteristics [26]. In contrast to trastuzumab emtansine, trastuzumab deruxtecan has a released payload that may easily cross the cell membrane, which potentially allows for potent cytotoxic effects on cancer cells regardless of target expression [27-29]. In addition, the released payload has a substantially shorter half-life, which may minimize systemic exposure and potential side effects [30]. In breast cancer, trastuzumab deruxtecan has been shown to exhibit a durable therapeutic activity in a population of heavily pre-treated patients (≥2 prior anti-HER2-based regimens) with advanced HER2-positive breast cancer [31]. This phase 2 study (II DESTINY-Breast01 trial) revealed that a response to trastuzumab deruxtecan was achieved in 60.9% of the patients of which 6% had a complete response (CR) while 54.9% of patients had a partial response [31]. The preliminary data from the II DESTINY-Breast01 trial were presented at the San Antonio 2019 meeting [32] and led to the accelerated approval by the Food and Drug Administration (FDA) in December 2019.

The results from another ongoing trial named Phase II DESTINY-Lung01 trial have just been presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program [33]. This trial showed that trastuzumab deruxtecan also achieved a clinically significant tumor response in patients with HER2-mutant advanced non-squamous NSCLC whose disease had progressed following one or more previous systemic therapies (chemotherapy or immunotherapy with immune checkpoint inhibitors against PD-1/PD-L1) [33]. The confirmed objective response rate (ORR) was achieved in 61.9% of patients treated with trastuzumab deruxtecan mono-therapy (6.4mg/kg). A disease control rate (DCR) of 90.5% with a median progression-free survival (PFS) of 14 months were remarkable achievements in this study. However, other relevant endpoints such as a median duration of response and overall survival (OS) have not been reached at the time of data cut-off [33]. Nevertheless, these encouraging results, after many failed trials and extensive research on HER2 in NSCLC [34-36], may pave a new way for the treatment of a small subset of NSCLC harboring HER2 gene mutations. Interestingly, for the predictive purposes HER2-overexpressing non-squamous NSCLC (defined as scores ≥2 and ≥3+ by immunohistochemistry/IHC) or non-squamous NSCLC harboring a HER2-activating mutation, were used in this trial. From the provided abstract [33], it is not clear whether the differences in a treatment response were observed between HER2-mutant NSCLC and HER2-overexpressing NSCLC (≥2 and ≥3+ scores by IHC). In contrast, an ongoing, phase II trial with trastuzumab deruxtecan in advanced gastric/GEJ carcinomas (DESTINY-Gastric01) enrolled only those patients whose cancers were HER2-positive (Score ≥3+ by IHC or ≥3+ with confirmatory HER2 amplification by in situ hybridization assay). A clinical trial on NSCLC with ADC trastuzumab emtansine (T-DM1) reported responses to the targeted drug only in HER2+ NSCLC while no responses were found in 2+ NSCLC cases [37]. It is well-known that HER2 status assessed by IHC (particularly score ≥2+) is not an optimal approach for selection of the patients having a mutant HER2 cancer as recently shown in case of colo-rectal carcinoma [38]. Apart from the well-documented examples of mutation-specific IHC antibodies (e.g. BRAF p.V600E,

**TABLE 1.** Overview of the anti-HER2 agents that have been approved in breast and gastric cancers

<table>
<thead>
<tr>
<th>Anti-HER2 agent</th>
<th>Structure</th>
<th>Mechanism of action</th>
<th>Approved indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trastuzumab</td>
<td>Monoclonal antibody</td>
<td>Immune-mediated response causing internalization and downregulation of HER2</td>
<td>HER2+ breast cancer</td>
</tr>
<tr>
<td>Pertuzumab</td>
<td>Monoclonal antibody</td>
<td>Prevents HER2-HER3 dimerization (combined with trastuzumab and docetaxel)</td>
<td>HER2+ breast cancer</td>
</tr>
<tr>
<td>Trastuzumab emtansine (ado-trastuzumab emtansine)</td>
<td>Antibody-drug conjugate (ADC)</td>
<td>Trastuzumab and DM1 (cytotoxic maytansinoid); DM1 binds microtubules and inhibits cell division in the tumor cells</td>
<td>HER2+ breast cancer*</td>
</tr>
<tr>
<td>Trastuzumab deruxtecan (DS-8201)</td>
<td>Antibody-drug conjugate (ADC)</td>
<td>Trastuzumab and a topoisomerase I inhibitor conjugate deruxtecan</td>
<td>HER2+ breast cancer*</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>Dual tyrosine kinase inhibitor</td>
<td>Blocks EGFR/HER2 protein kinase activity</td>
<td>ER+/EGFR+/HER2+ breast cancer</td>
</tr>
<tr>
<td>Neratinib</td>
<td>Dual tyrosine kinase inhibitor</td>
<td>Blocks EGFR/HER2 activity by covalently binding with a cysteine side chain in those receptors</td>
<td>HER2+ breast cancer</td>
</tr>
<tr>
<td>Tucatinib</td>
<td>Tyrosine kinase inhibitor</td>
<td>Highly selective inhibitor of the kinase domain of HER2 receptor</td>
<td>HER2+ breast cancer**</td>
</tr>
</tbody>
</table>

ER = Estrogen receptor; EGFR = Epidermal growth factor receptor; HER2 = Human epidermal growth receptor 2.

*Breakthrough Therapy Designation (BTD) has been granted for this drug in May 2020 for the treatment of advanced/metastatic gastric/GEJ carcinomas and non-small cell lung carcinomas harboring HER2 gene mutations. Trastuzumab deruxtecan (DS-8201) has been approved by FDA for metastatic HER2+ breast cancer in December 2019.

**The approval for this drug was granted by FDA in April 2020 and was based on the clinical trial HER2CLIMB, ClinicalTrials.gov number, NCT02614794 [54].
IDH1 p.R132H, or H3K27M), which tend to correlate well with the specific mutations [39]. IHC antibodies that target specific proteins may lack correlation with the DNA-level mutational events. There are several possible reasons including the fact that the mutation may not result in (increased) protein expression (e.g. due to transcriptomic silencing of genetic variant or discordance between the DNA alterations and RNA expression) [40], hence IHC may be consequently negative/low positive; another possibility is that the antibody may target a specific epitope that may or may not be altered by the mutation. In case of trastuzumab deruxtecan, another important therapeutic target is TOP1, which is inhibited by the ADC payload deruxtecan. TOP1 is an enzyme with an active role in DNA function by the cleavage one of the two backbones in double-stranded DNA enabling the double helix to be untwisted [41]. TOP1 status has been extensively studied by immunohistochemistry, most notably in colorectal cancer where it has been shown to predict a response to irinotecan-based chemotherapy [42,43]. It is well-known that irinotecan may reversibly stabilize the TOP1 cleavable complex, resulting in single-strand DNA breaks and ultimate cell death [44]. In addition, a high TOP1 expression has also been demonstrated in several other cancers, including small cell lung, gastric/gastroesophageal, esophageal, thymic, anal, breast, prostate and poorly differentiated neuroendocrine carcinomas [25]. The same study as well as several other studies also revealed a common TOP1 overexpression in NSCLC [45,46]. Another ADC sacituzumab govitecan-hziy (TRODELVY, Immunomedics, Inc.) was recently approved for the patients with metastatic triple-negative breast cancer (TNBC). It represents an anti-Trop-2 (=trophoblast cell-surface antigen 2) ADC and contains irinotecan metabolite, SN-38 that is conjugated to a humanized anti-TROP-2 antibody (sacituzumab govitecan) [47]. Although both Trop-2 and TOP1 expression have been well-documented in various cancers including breast cancer [25,48-52], predictive testing was not conducted in this trial (IMMU-132-01 (NCT 01631552) clinical trial [53]).

In short, recent data indicate that HER2 mutations may be successfully targeted with the available anti-HER2 treatment modalities. ADC such as trastuzumab deruxtecan represent novel promising therapeutic means for the patients with advanced non-squamous NSCLC. Despite the remarkable achievements, we believe that further efforts should be made to optimize the treatment with these ADC where molecular targets are well characterized and may be easily assessed prior to targeted treatments.

REFERENCES
